Gregory Scagnelli, MD
Pediatric Gastroenterology · Binghamton, NYNPI 1093707481
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Johnson & Johnson at 24.2% of the total. Reporting peaked in 2019 at $1,525 and has fallen 76.2% since, to $364 in 2025.
Across 142 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$601
- AbbVie$463
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$401
- Takeda Pharmaceuticals U.S.A., Inc.$208
- Daiichi Sankyo Inc.$120
- Gilead$110
- plus $585 from 14 others
What the payments were for
- Food & beverage$2,42197%
- Education$673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 29 | $601 |
| AbbVie(2 entities) | 24 | $463 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $401 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $208 |
| Daiichi Sankyo Inc. | 6 | $120 |
| Gilead | 7 | $110 |
| E.r. Squibb & Sons, L.L.C. | 1 | $107 |
| Intercept Pharmaceuticals, Inc. | 7 | $102 |
| Janssen Scientific Affairs, LLC | 2 | $68 |
| UCB, Inc. | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $54 |
| Merck | 3 | $47 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| QOL Medical, LLC | 2 | $29 |
| Braintree Laboratories, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Mirum Pharmaceuticals, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $16 |
| Concordia Pharmaceuticals Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,488 in reported general payments places this provider in the 75th percentile of 143 pediatric gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 26 | $17 |
Paid to pharmacies, not to this prescriber.
Other pediatric gastroenterology in Binghamton
- Sivan KinbergNew York$261K
- Tuvia MarcianoMineola$249K
- Mirna ChehadeNew York$217K
- Michael DolingerNew York$191K
- Thomas WallachNew York$160K
- Neal LeleikoNew York$157K
- Shari Sheflin FindlingNew Hyde Park$143K
- William TreemBrooklyn$118K
- Nanda KerkarRochester$48K
- Daniel GelfondBatavia$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.